News Conference News ACC 2025 Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI Caitlin E. Cox March 30, 2025
News Opinion Editor's Corner ACC 2025 What’s Going to Be Hot at ACC 2025? Michael O'Riordan March 26, 2025
News Daily News Food Insecurity in Adulthood Signals Greater Risk of Later CVD Todd Neale March 12, 2025
News Daily News Years After Radiation Therapy, Echo Parameters Worse in Breast Cancer Patients Caitlin E. Cox March 11, 2025
News Daily News CV Screening, Care at UK Football Club Made Inroads Against HF Caitlin E. Cox March 07, 2025
News Daily News Sotagliflozin Reduces Ischemic Risk in SCORED Analysis Yael L. Maxwell February 25, 2025
News Conference News THT 2025 Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity Todd Neale February 12, 2025
Presentation THT 2025 The Diabetes Paradox: Outcomes in Heart Failure Patients With Diabetes Presenter: Navneet Sandhu February 12, 2025
Presentation THT 2025 Impact of Sitagliptin on Long-Term Outcomes in Heart Failure With Reduced Ejection Fraction in Type 2 Diabetes Patients: A Retrospective Cohort Study Presenter: Thitiphan Srikulmontri February 12, 2025
Presentation THT Abstracts 2025 The Diabetes Paradox: Outcomes in Heart Failure Patients With Diabetes Presenter: Navneet Sandhu February 11, 2025
Presentation THT Abstracts 2025 Impact of Sitagliptin on Long-Term Outcomes in Heart Failure With Reduced Ejection Fraction in Type 2 Diabetes Patients: A Retrospective Cohort Study Presenter: Thitiphan Srikulmontri February 11, 2025
News Daily News CVD Hospitalization in Older Adults Higher in US Than in Denmark Michael O'Riordan February 07, 2025
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for January 2025 Shelley Wood January 31, 2025
News Conference News STS 2025 Transplant Recipients on Medicaid More Likely to Develop Allograft Vasculopathy Yael L. Maxwell January 30, 2025
News Daily News AHA Stats Show CV Health of Americans Remains Dire Michael O'Riordan January 28, 2025
News Daily News Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study Michael O'Riordan January 22, 2025